A recent Mendelian randomization study showed that genetically predicted insulin-like growth factor 1 levels were significantly positively associated with prostate cancer in the UK Biobank and non-significantly positively associated with prostate cancer in the PRACTICAL consortium and BioBank Japan [48]. The gene discussed is IGF1; the disease is prostate carcinoma.